NICE sets 10 Nov committee and Jan 2027 date for Foundayo (orforglipron)
NICE's appraisal of orforglipron for overweight and obesity (GID-TA11650) lists a second Technology Appraisal Committee A meeting on 10 November 2026, with expected publication on 27 January 2027. Foundayo is already on private UK prescription after the August MHRA licence, but NHS access still waits on this guidance.
Source: NICE (5 Nov 2026).